At an FDA-and industry-sponsored workshop held in April 2005, industry representatives and regulators from around the world explored issues of pharmacogenomics to drug development. In an EELS article, Mendrick et al. (pp 154-157) summarize a workshop discussion about setting international regulatory rules for drug development. Case studies discussed drug approval related to pharmacogenomic testing, the ramifications of one agency governing different populations, and biomarkers influence on the timing of the regulatory process. Overall, there was a consensus urging development of global strategies, and also a recognition that pharmacogenomics demands individual consideration for each drug trial.
One database
The emergence of genomics as a science can also improve pharmacovigilance. Farahani and Levine (pp 158-161) suggest that improved drug safety is possible through international coordination between networks of genomic information and those containing drug safety data. Genetic and tissue sample collections are known to vary widely in size and data, Genomic data drawn from these samples can make pharmacovigilance even more sensitive and precise. Large databases have already proven helpful in identifying population-specific drug interactions, and additional genomic data could enhance this ability. The authors urge regulatory bodies to create a framework for connecting the disparate collections.
History lesson
The word 'pharmacogenetics' was coined in 1959, but the idea of personalized medicine was conceived decades earlier. In this review, pharmacogenetics pioneer Kalow (pp 162-165) briefly describes the development of pharmacogenetics, pharmacogenomics, and personalized medicine. Kalow explains that there are limitations to single-gene analyses in patient treatment and that pharmacogenomics grew from the realization that multiple gene mutations need to be considered.
Trial by design
Genomic signature is a powerful tool for increasing drug efficacy and reducing potential adverse reactions. Simon and Wang (pp 166-173) present clinical trial designs that focus on genomic classifiers, using statistical methods to associate target patients with treatment response. Specifically, they recommend focusing on small, drug-responsive patient subsets during phase III of oncological drug trials. The authors present prospective and retrospective designs and the conditions under which their usage is appropriate.
b-Blockers b-Blockers are commonly used to treat hypertension, arrhythmias, and angina, and used to reduce a rapid heart rate. Beitelshees et al. (pp 174-179) studied the variation of negative chronotropic effects in hypertensive patients treated with metoprolol. The authors sought to determine if these heart rate modulation variations were associated with polymorphisms Arg389Gly and Ser49Gly. Adjusting for blood plasma concentrations revealed that the polymorphisms did not significantly influence metoprolol's affect on heart rate. Without adjusting for plasma concentrations, metoprolol seemed to slow the heart rate. The authors conclude that pharmacogenetic associations with one phenotype cannot be applied to all phenotypes and that drug targets studies should also include drug exposure.
Methamphetamine psychosis
Methamphetamine (MAP), a non-opiate, is the second most abused drug in the world, and more than 80% of users experience MAP psychosis. studied the connection between the mopioid receptor gene (OPRM1) and MAP dependence and psychosis. The authors identified four new sets of polymorphisms in linkage disequilibrium in Japanese patients with MAP dependence/psychosis. The relationship between OPRM1 and MAP dependence/psychosis implies interaction between opioids and dopamine systems in non-opiate dependence.
Early cancer detection
Ovarian cancer is particularly difficult to diagnose in its initial stages. investigated polymorphisms in four estrogen metabolism genes to determine risks of ovarian and endometrial cancer development. The authors studied a Russian population from the Novosibirsk region where incidences of these hormone-dependent cancers are rising dangerously fast. Women with malignant ovarian and endometrial tumors had a high frequency of the SULT1A1 G and CYP1A2*1F C alleles than those without.
Nicotine replacement therapy Surgeon General's warning: smoker response to nicotine replacement therapy (NRT) is uneven. In a follow-up study, found that smokers with the gene variation DRD2-141 Ins/Del were found to respond better to treatment and abstain from smoking longer. A significant amount of smokers (62%) were homozygous for the FREQ rs1054879 A/A SNP and who also carried DRD2-141 Del abstained from smoking. Although the authors note several study limitations, genetic variation in signaling transduction pathways may predict treatment response of other dopaminergic diseases.
Opioid potency
Common SNPs in the OPRM1 gene could affect morphine's ability to relieve pain. Lötsch and Geisslinger (pp 200-210) genotyped a pooled data set from healthy subjects to determine the frequency and impact of 24 candidate mutations. Mutations present in at least 5% of subjects were considered to potentially affect opioid therapy potency, and three SNPs met this criterion. Of them, only 118A4G was confirmed to have an impact, decreasing efficacy of both morphine and its metabolite, M6G.
Gilbert's syndrome UGT1A1 and NAT2 are metabolic pathways that may be related to adverse drug reactions in different ways. To examine both simultaneously, Hermann et al. (pp 211-219) compared the pharmacokinetics of retigabine in four affected groups. Carriers of Gilbert's syndrome (GS), a condition marked by impaired glucuronidation, were identified by reduced gene expression in the UGT1A1 metabolic pathway. The authors focused on the pharmacokinetics of AWD21-360, a specific metabolite of retigabine. The presence of GS did not affect metabolism of retigabine or AWD21-360, suggesting that the NAT2 pathway compensates for GS patients regardless of their acetylation rate. 
